Brief: Fractyl Health Nomination Of RJVA-002, A GIP/GLP-1 Dual Agonist, As Its First Pancreatic Gene Therapy Candidate For Obesity
04/11/2024 21:18
Nov 4 (Reuters) - Fractyl Health Inc GUTS.O :
* FRACTYL HEALTH: NOMINATION OF RJVA-002, A GIP/GLP-1 DUAL
AGONIST, AS ITS FIRST PANCREATIC GENE THERAPY CANDIDATE FOR
OBESITY
* FRACTYL HEALTH: RESULTS SHOW SUSTAINED MAINTENANCE OF
WEIGHT
LOSS, BLOOD SUGAR LEVELS AT WEEK 13 IN DIO MICE GIVEN RJVA-001 &
CONTINUING HIGH FAT DIET
Source text: ID:nGNX7dYsP9
Further company coverage: GUTS.O
((Reuters.Briefs@thomsonreuters.com;))